293780 — AptaBio Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- KR₩285bn
- KR₩281bn
- KR₩324m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS/A |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,019 | 341 | 224 | 48.4 | 324 |
Cost of Revenue | |||||
Gross Profit | — | — | — | — | 78.5 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 8,170 | 6,406 | 11,591 | 9,555 | 16,697 |
Operating Profit | -7,151 | -6,065 | -11,367 | -9,507 | -16,374 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6,298 | -3,919 | -10,689 | -10,565 | -14,692 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6,298 | -3,919 | -10,689 | -10,565 | -12,062 |
Net Income Before Extraordinary Items | |||||
Net Income | -6,298 | -3,919 | -10,689 | -10,565 | -12,062 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -6,298 | -3,919 | -10,689 | -10,565 | -11,866 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -318 | -178 | -712 | -474 | -532 |
Dividends per Share |